Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveillance)
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 147
- Registration Number
- NCT02415712
- Locations
- 🇯🇵
Takeda Sponsored Site, Tokyo, Japan
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TAK-020 PlaceboDrug: TAK-020
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 120
- Registration Number
- NCT02413255
Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria
Phase 2
Withdrawn
- Conditions
- Diabetic Nephropathy
- Interventions
- Drug: MLN1202 PlaceboDrug: MLN1202
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Takeda
- Registration Number
- NCT02410499
A Bioequivalence Study of TAK-536 Pediatric Formulation
Phase 1
Completed
- Conditions
- Japanese Healthy Adult Males
- Interventions
- Drug: TAK-536 TabletDrug: TAK-536 Dry Syrup FormulationDrug: TAK-536 Ganule Formulation
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 52
- Registration Number
- NCT02401464
A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.
Phase 4
Withdrawn
- Conditions
- Essential Hypertension With Stable Angina and Dyslipidemia
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Takeda
- Registration Number
- NCT02400775
Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TAK-385 T2 FormulationDrug: TAK-385 T4 Formulation BDrug: TAK-385 T4 Formulation C
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 54
- Registration Number
- NCT02396147
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
Active, not recruiting
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 757
- Registration Number
- NCT02394834
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Phase 3
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 823
- Registration Number
- NCT02394795
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 7
- Registration Number
- NCT02393378
A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 493
- Registration Number
- NCT02389816
© Copyright 2025. All Rights Reserved by MedPath